Gemini Theranostics developed a theranostic platform targeting the Follicle Stimulating Hormone Receptor (FSHR), a therapeutic target that is expressed in 50-70% of ovarian cancer patients.

Next-generation gene promoters for more stable and higher recombinant protein expression.

Pionering whole genome sequencing based genotoxicity testing

GlycoCheck measures and analyzes microvascular health, and objectively reports a MicroVascular Health Score (MVHS)

GlycoDiagnostics developed a novel, non-invasive diagnostic test based on a glycan biomarker that enables early and accurate detection of fibrosis. The GlycoDiagnostics test leverages specific glycosylation signatures that outperform existing tests such as FIB-4 and FibroScan in a proof-of-concept retrospective clinical study. It enables more reliable and effective patient identification for clinical trials, reducing missed cases, accelerating recruitment, and lowering costs. The test is minimally invasive, compatible with plasma or dried blood spots, and scalable for multicenter trials.

A robust patient monitoring device which is highly reliable and easy to use to prevent children in low and middle income countries unnecessary dying from severe bacterial infections.

HeartSmart revolutionizes cardiac research with a miniaturized heart tissue model that accurately mimics fibrosis and enables reliable, predictive drug testing for heart failure therapies.

HELIA Biomonitoring’s mission is to enable continuous monitoring of therapeutic drug concentrations, organ function markers, and treatment response markers for personalized patient care.

Liver toxicity is the main safety reason for drug attrition in clinical trials, causing 1 in every 13 drugs to fail. We have developed a novel, human liver model in a dish called hello which accurately predicts the toxicity of drugs.

A medical device for standardised capillary blood sampling without trained personnel, integrated into routine hospital and laboratory workflows.